Hydrogen, the Next Neuroprotective Agent?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

A Marchidann serves as the principal investigator of the clinical trial Neuroprotection in Acute Ischemic Stroke (H2M) sponsored by Stony Brook University in collaboration with Korea Institute of Science and Technology, was principal investigator at SUNY Downstate for the Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial (POINT) and receives publishing fees from MedLink for annual updates not related to the topic. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

A Marchidann serves as the principal investigator of the clinical trial Neuroprotection in Acute Ischemic Stroke (H2M) sponsored by Stony Brook University in collaboration with Korea Institute of Science and Technology, was principal investigator at SUNY Downstate for the Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial (POINT) and receives publishing fees from MedLink for annual updates not related to the topic. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.